Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations

Papillary craniopharyngiomas (PCPs) are characterized by the presence of BRAF V600E mutations, which are emerging as a useful guide for diagnosis and treatment decision making. The ongoing multicenter phase 2 Alliance A071601 trial is evaluating the efficacy of BRAF and mitogen-activated protein kin...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer
Prif Awduron: Juratli, Tareq A., Jones, Pamela S., Wang, Nancy, Subramanian, Megha, Aylwin, Simon J.B., Odia, Yazmin, Rostami, Elham, Gudjonsson, Olafur, Shaw, Brian L., Cahill, Daniel P., Galanis, Evanthia, Barker, Fred G., Santagata, Sandro, Brastianos, Priscilla K.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7032527/
https://ncbi.nlm.nih.gov/pubmed/31314136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32197
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg